公开(公告)号：US5145686A

公开(公告)日：1992-09-08

申请号：US818501

申请日：1992-01-08

Applicant: David F. Horrobin ,  Julian Lieb

Inventor： David F. Horrobin ,  Julian Lieb

IPC: A61K8/19 ,  A61K8/36 ,  A61K8/362 ,  A61K8/365 ,  A61K8/368 ,  A61K8/67 ,  A61K8/92 ,  A61K31/19 ,  A61K31/195 ,  A61K31/20 ,  A61K33/00 ,  A61K33/30 ,  A61K36/185 ,  A61K45/06 ,  A61Q5/00 ,  A61Q19/00

CPC classification number: A61K45/06 ,  A61K31/195 ,  A61K31/20 ,  A61K33/00 ,  A61K33/30 ,  A61K36/185 ,  A61K8/19 ,  A61K8/361 ,  A61K8/362 ,  A61K8/365 ,  A61K8/368 ,  A61K8/67 ,  A61K8/922 ,  A61Q19/00 ,  A61Q5/00 ,  A61K2800/782

Abstract: Topical pharmaceutical compositions for the treatment of lesions of the skin or mucous membranes containing a physiologically acceptable lithium salt together with at least one substance selected from substances capable of selectively increasing the in vivo level of E-series prostaglandins, substances capable of inhibiting cyclooxygenase enzyme, substances capable of inhibiting the formation of lipoxygenase products, and lysine.

Abstract translation: 用于治疗含有生理上可接受的锂盐的皮肤或粘膜损伤的局部药物组合物以及选自能够选择性地增加E系列前列腺素的体内水平的物质，能够抑制环加氧酶的物质的至少一种物质， 能够抑制脂氧合酶产物形成的物质和赖氨酸。

公开(公告)号：US4868212A

公开(公告)日：1989-09-19

申请号：US307952

申请日：1989-02-09

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A23D9/00 ,  A23L1/30 ,  A23L1/325 ,  A23L1/48 ,  A61K31/16 ,  A61K31/20 ,  A61K31/22 ,  A61K31/23 ,  A61K31/557 ,  A61K35/56 ,  A61K35/60 ,  A61K36/00 ,  A61K36/185 ,  A61K38/00 ,  A61P3/08 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/30 ,  A61P27/16 ,  A61P35/00 ,  A61P37/08

CPC classification number: A61K35/60 ,  A23D9/00 ,  A61K31/20 ,  A61K31/23 ,  A61K31/557 ,  A61K36/185 ,  Y10S514/861 ,  Y10S514/866

Abstract: A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.

公开(公告)号：US4855136A

公开(公告)日：1989-08-08

申请号：US92191

申请日：1987-09-02

Applicant: David F. Horrobin ,  Y. Sheng Huang

Inventor： David F. Horrobin ,  Y. Sheng Huang

IPC: A61K31/20 ,  A61K31/202 ,  A61K33/06 ,  A61K33/10 ,  A61K36/00 ,  A61K36/185 ,  A61K36/30 ,  A61P3/00 ,  A61P3/14 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P43/00

CPC classification number: A61K36/185 ,  A61K31/20 ,  A61K33/06 ,  A61K36/30

Abstract: Combinations of gamma-linolenic acid (GLA) and calcium, presented for administration in assimilable dosage unit form in doses of 1 mg to 100 g GLA and 1 mg to 20 g calcium daily, for example, for the treatment of osteoporosis and other bone disorders involving calcium loss from the bones, of premenstrual syndrome, or of hypertension.

Abstract translation: 以可同化剂量单位形式给予γ-亚麻酸（GLA）和钙的组合，每天以1mg至100g GLA和1mg至20g钙的剂量形式，例如用于治疗骨质疏松症和其他骨骼疾病 涉及骨骼钙，经前期综合征或高血压的钙损失。

公开(公告)号：US4248872A

公开(公告)日：1981-02-03

申请号：US69493

申请日：1979-08-24

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/415 ,  A61K31/505

CPC classification number: A61K31/415 ,  A61K31/505

Abstract: A method for the treatment of anxiety which consists of administering dipyridamole or imidazole or a derivative thereof. It has been found that known anti-anxiety agents appear to act as competitive antagonists of thromboxane A2 (TXA2), and it is therefore believed that dipyridamole and imidazole, which inhibit the formation of TXA2, will be effective in the treatment of anxiety.

Abstract translation: 治疗焦虑症的方法，其由施用双嘧达莫或咪唑或其衍生物组成。 已经发现已知的抗焦虑剂似乎作为血栓素A2（TXA2）的竞争性拮抗剂，因此认为抑制TXA2形成的双嘧达莫和咪唑在治疗焦虑方面是有效的。